We serve N-(m-tolyl)dibenzo[b,d]furan-4-amine CAS:1609080-03-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![N-(m-tolyl)dibenzo[b,d]furan-4-amine](https://a.dearchem.com/uploads/userup/0/15H4cL0-BX.png)
Contact us for information like N-(m-tolyl)dibenzo[b,d]furan-4-amine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-(3-Methylphenyl)-4-dibenzofuranamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-DBFMA Use and application,4-DBFMA technical grade,usp/ep/jp grade.
Related News: In addition to APIs, a variety of pharmaceutical excipients are contained in the medicine.3-(3-chloropropyl)-7,8-dimethoxy-1H-3-benzazepin-2-one manufacturer In addition to APIs, a variety of pharmaceutical excipients are contained in the medicine.9-Bromo-7,7-dimethyl-7H-benzo[c]fluorene supplier The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.D-Alanine vendor The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.
